Skip to content

Study · Measured the body's own peptide · 1993

2 results

Decreases in substance P and vasoactive intestinal peptide concentrations in plasma of stroke-prone spontaneously hypertensive rats.

Mori K, Asakura S, Ogawa H, Sasagawa S, Takeyama M

Japanese heart journal1 Nov 1993Cited by 4 (Europe PMC)

PMID7513029 (opens in a new tab)DOI10.1536/ihj.34.785 (opens in a new tab)PepBankPUB-07513029
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01AnimalEndogenous levelAnimal study (in vivo)Other

    Mean plasma VIP concentration was significantly lower in stroke-prone spontaneously hypertensive rats than in Wistar-Kyoto rats.

    In plain wordsIn rats, the body's own VIP level in blood was lower in stroke-prone hypertensive rats than in normal-pressure rats.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseMean plasma VIP concentration
    Study

    ratn = 119

    stroke-prone spontaneously hypertensive rats (SHRSP) and Wistar-Kyoto rats
    Comparator
    Wistar-Kyoto rats
    Outcome group
    Endogenous peptide levels · Cardiovascular

    Measurements

    plasma VIP
    0.8 fmol/ml
    SHRSP
    plasma VIP
    1.01 fmol/ml
    WKY

    Source sentences

    Summary
    The mean plasma VIP concentrations of SHRSP (n = 61) and WKY (n = 58) were 0.80 +/- 0.25 fmol/ml and 1.01 +/- 0.32 fmol/ml, respectively. The value of SHRSP was significantly lower than that of WKY (p < 0.01).
    1 context sentence
    Summary · context
    In order to study alterations of peripheral substance P (SP) and vasoactive intestinal peptide (VIP) in the immunoreactive nervous system in essential hypertension, plasma SP and VIP concentrations in stroke-prone spontaneously hypertensive rats (SHRSP) at 8, 12, 18, 28, 30, 35 and 48 weeks of age a…

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  2. 02AnimalEndogenous levelAnimal study (in vivo)Other

    Plasma VIP was lower in stroke-prone spontaneously hypertensive rats than in Wistar-Kyoto rats at all ages studied.

    In plain wordsIn rats, the body's own VIP level in blood was lower in hypertensive rats at every age studied.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreasePlasma VIP concentration across ages
    Study

    ratn = 119

    stroke-prone spontaneously hypertensive rats (SHRSP) and Wistar-Kyoto rats
    Comparator
    Wistar-Kyoto rats
    Outcome group
    Endogenous peptide levels · Cardiovascular

    Source sentences

    Summary
    These decreases in plasma SP and VIP concentrations of SHRSP were observed at all ages.
    1 context sentence
    Summary · context
    In order to study alterations of peripheral substance P (SP) and vasoactive intestinal peptide (VIP) in the immunoreactive nervous system in essential hypertension, plasma SP and VIP concentrations in stroke-prone spontaneously hypertensive rats (SHRSP) at 8, 12, 18, 28, 30, 35 and 48 weeks of age a…

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.